Eli Lilly to Sell Weight-Loss Drugs Directly on Hims & Hers Platform

Deep News11-06

Eli Lilly announced on Friday that it has reached a cooperation agreement authorizing telehealth platform Hims & Hers Health to sell obesity drugs Zepbound and Foundayo directly on its platform; following the news, the telehealth company's shares rose more than 7%.

Previously, patients who wanted to purchase these two Eli Lilly drugs on the Hims & Hers platform had to be redirected to Eli Lilly's own self-pay purchasing platform, LillyDirect. This move puts Eli Lilly on the same track as its Danish competitor Novo Nordisk.

Novo Nordisk has been selling Wegovy and Ozempic through Hims & Hers since March of this year; prior to that, Novo Nordisk had sued the telehealth platform for selling compounded versions of its drugs. Michael Cherny, an analyst at Leerink Partners, commented that Eli Lilly's partnership is "clearly a positive." The agreement means Hims & Hers has secured legitimate supply channels from both major GLP-1 pharmaceutical leaders. After the platform previously exited the large-scale compounded drug business, this partnership helps provide patients with more original branded weight-loss prescription drugs.

Eli Lilly leads the obesity drug market with its highly effective injectable Zepbound; however, Novo Nordisk has higher sales of oral weight-loss drugs in the United States. Eli Lilly's oral drug Foundayo was launched in April, approximately three months after Novo Nordisk's oral Wegovy hit the market.

Ilya Yuffa, President of Eli Lilly's U.S. division, said: "Currently, the process for users on the Hims & Hers platform to obtain Eli Lilly drugs is not smooth enough." He stated that any obstacle in the consumer purchasing process increases the likelihood of users abandoning the purchase. Yuffa also explained that as a condition of the partnership, Hims & Hers has committed to no longer selling compounded versions and counterfeit products of Eli Lilly's obesity drugs.

Self-pay pricing: Eli Lilly's oral weight-loss drug Foundayo starts at $149 per month, and the injectable GLP-1 drug Zepbound starts at $299 per month, consistent with pricing on the LillyDirect platform. Novo Nordisk drug pricing on the platform: oral Wegovy starts at $149 per month, and the Wegovy injection pen starts at $199 per month.

According to Eli Lilly data, approximately 40%–45% of Zepbound's sales come from self-pay channels. Analysts believe that many corporate employers are canceling insurance reimbursement for weight-loss drugs to control costs, and Hims & Hers is expected to benefit from this next year. Last week, Eli Lilly raised its full-year revenue guidance by $5 billion due to booming demand for its injectable weight-loss drugs. In the massive and continuously expanding obesity drug market, Eli Lilly, with its leading position, has reached a market capitalization of $1.2 trillion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment